315 related articles for article (PubMed ID: 26840088)
1. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.
Heo TH; Wahler J; Suh N
Oncotarget; 2016 Mar; 7(13):15460-73. PubMed ID: 26840088
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
3. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
4. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.
Karczewska A; Nawrocki S; Breborowicz D; Filas V; Mackiewicz A
Cancer; 2000 May; 88(9):2061-71. PubMed ID: 10813718
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
6. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
8. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies.
Kalai M; Montero-Julian FA; Brakenhoff JP; Fontaine V; De Wit L; Wollmer A; Brailly H; Content J; Grötzinger J
Eur J Biochem; 1997 Nov; 249(3):690-700. PubMed ID: 9395315
[TBL] [Abstract][Full Text] [Related]
10. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model.
Kovacs E
ScientificWorldJournal; 2006 Aug; 6():888-98. PubMed ID: 16892169
[TBL] [Abstract][Full Text] [Related]
12. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.
Li H; Wang H; Nicholas J
J Virol; 2001 Apr; 75(7):3325-34. PubMed ID: 11238858
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.
Jiang XP; Yang DC; Elliott RL; Head JF
Anticancer Res; 2011 Sep; 31(9):2899-906. PubMed ID: 21868536
[TBL] [Abstract][Full Text] [Related]
14. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization.
Suthaus J; Adam N; Grötzinger J; Scheller J; Rose-John S
Eur J Cell Biol; 2011; 90(6-7):495-504. PubMed ID: 21176991
[TBL] [Abstract][Full Text] [Related]
15. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Chen X; Tian J; Su GH; Lin J
Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
[TBL] [Abstract][Full Text] [Related]
16. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
17. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
[TBL] [Abstract][Full Text] [Related]
18. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia.
Zhang Z; Gao Y; Zhang L; Jia L; Wang P; Zhang L; Li H
Hypertens Pregnancy; 2013 Aug; 32(3):270-80. PubMed ID: 23782174
[TBL] [Abstract][Full Text] [Related]
19. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]